PapersFlow Research Brief
Breast Cancer Treatment Studies
Research Guide
What is Breast Cancer Treatment Studies?
Breast Cancer Treatment Studies are clinical and molecular research investigations evaluating therapies such as chemotherapy, hormonal therapy, surgery, radiation, and targeted agents to assess their efficacy, recurrence risk, and survival outcomes in breast cancer patients.
Breast Cancer Treatment Studies encompass 111,340 published works focused on treatment response evaluation, prognostic factors, gene expression profiling, and long-term survival outcomes. Therasse et al. (2000) in "New Guidelines to Evaluate the Response to Treatment in Solid Tumors" established standardized criteria for measuring tumor shrinkage from cytotoxic agents, cited 15,648 times. Nishimura et al. (2013) in "Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer" identified factors linked to recurrences beyond 10 years post-treatment.
Research Sub-Topics
Neoadjuvant Chemotherapy in Breast Cancer
This sub-topic examines preoperative chemotherapy regimens to shrink tumors before surgery in breast cancer patients. Researchers study response rates, pathological complete response predictors, and survival outcomes across subtypes.
Breast Cancer Gene Expression Profiling
This area focuses on microarray and RNA-seq analyses to classify breast cancer subtypes like luminal and basal-like. Studies develop prognostic signatures such as Oncotype DX for recurrence risk prediction.
HER2-Targeted Therapies in Breast Cancer
Researchers investigate monoclonal antibodies like trastuzumab and tyrosine kinase inhibitors such as lapatinib for HER2-positive breast cancer. Trials assess combinations with chemotherapy and resistance mechanisms.
Endocrine Therapy Resistance in Breast Cancer
This sub-topic explores mechanisms of resistance to tamoxifen and aromatase inhibitors in ER-positive tumors. Research identifies ESR1 mutations, PI3K pathway alterations, and novel CDK4/6 inhibitors.
Breast Cancer Histological Grading Systems
Studies refine Nottingham and Scarff-Bloom-Richardson grading based on tubule formation, nuclear pleomorphism, and mitotic counts. Researchers develop automated AI-based grading for reproducibility and prognostication.
Why It Matters
Breast Cancer Treatment Studies directly inform clinical guidelines for surgery, chemotherapy, and targeted therapies, improving patient selection and outcomes in oncology practice. Fisher et al. (2002) in "Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer" demonstrated that lumpectomy plus irradiation yields equivalent survival to mastectomy when margins are clear, supporting breast-conserving surgery in over 6110-cited analyses. Paik et al. (2004) in "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" validated a 21-gene recurrence score that quantifies distant recurrence risk in estrogen-receptor-positive cases, guiding adjuvant therapy decisions. Recent trials like DESTINY-Breast04 show trastuzumab deruxtecan improving overall survival versus physician's choice chemotherapy in HER2-low metastatic breast cancer. These studies enable personalized staging per Amin et al. (2017) in "The Eighth Edition AJCC Cancer Staging Manual," bridging population-based to individualized prognostication.
Reading Guide
Where to Start
"New Guidelines to Evaluate the Response to Treatment in Solid Tumors" by Therasse et al. (2000) first, as it provides foundational criteria for assessing any treatment response across solid tumors including breast cancer, essential before diving into specific studies.
Key Papers Explained
Therasse et al. (2000) "New Guidelines to Evaluate the Response to Treatment in Solid Tumors" sets response criteria foundational for trials like Fisher et al. (2002) "Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation," which applies them to surgical outcomes. Sørlie et al. (2001) "Gene expression patterns of breast carcinomas distinguish tumor subclasses" introduces molecular subtyping, extended by van 't Veer et al. (2002) "Gene expression profiling predicts clinical outcome of breast cancer" and van de Vijver et al. (2002) "A Gene-Expression Signature as a Predictor of Survival," which validate signatures for prognosis outperforming clinical factors. Paik et al. (2004) "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" builds on these for recurrence risk in specific subtypes.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
DESTINY-Breast04 and DESTINY-Breast11 preprints (2025) evaluate trastuzumab deruxtecan in HER2-low and high-risk HER2-positive early breast cancer, showing survival gains over standard regimens. PALLAS 5-year follow-up (2025) assesses palbociclib plus endocrine therapy iDFS in HR-positive cases. A-BRAVE trial (2025) tests avelumab adjuvant in high-risk triple-negative breast cancer; HER2CLIMB-05 explores TUKYSA maintenance in HER2-positive metastatic disease.
Papers at a Glance
In the News
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
Chemotherapy remains a standard treatment option for metastatic triple-negative breast cancer (TNBC) but is associated with limited survival. Although some targeted antibody–drug conjugates have de...
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
Here, we describe the primary results of the ATRACTIB phase 2 study, which demonstrated encouraging antitumor activity and a manageable safety profile of the atezolizumab, paclitaxel and bevacizuma...
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician’s choice of chemo...
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial - PubMed
**Background:**Neoadjuvant standard-of-care for HER2-positive early-stage breast cancer is trastuzumab + pertuzumab with polychemotherapy; however, existing regimens have high toxicity burdens and ...
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
# TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial Tuesday, October 14, 2025 - 06:45am
Code & Tools
## Repository files navigation # BCT > Machine learning toolkit designed to support data scientists in breast cancer detection, classification an...
Breast cancer diagnosis and treatment planning involves a complex workflow that requires data from disparate healthcare system and demands precisio...
**Background:** Prognostic stratification of breast cancers remains a challenge to improve clinical decision making. We employ machine learning on ...
The **Breast Sensitivity Signature Collection (SSc breast)** contains 1,372 gene signatures that reflect the **transcriptional differences between ...
Grootes, I., Wishart, G.C. and Pharoah, P.D.P., 2024. An updated PREDICT breast cancer prognostic model including the benefits and harms of radioth...
Recent Preprints
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician’s choice of chemo...
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial - PubMed
**Background:**Neoadjuvant standard-of-care for HER2-positive early-stage breast cancer is trastuzumab + pertuzumab with polychemotherapy; however, existing regimens have high toxicity burdens and ...
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer - PubMed
**Conclusions:**Trastuzumab deruxtecan plus pertuzumab led to a significantly lower risk of progression or death than THP when used as first-line treatment for HER2-positive advanced or metastatic ...
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13) - PubMed
**Background:**In the phase III PALLAS trial, the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) did not improve short-term invasive disease-free survival (iDFS) compared wit...
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients - PubMed
FormatAbstractPubMedPMID ## Abstract **Background:**The A-BRAVE trial evaluated the efficacy of avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody, as adjuvant treatment of patients with ...
Latest Developments
Recent developments in breast cancer research as of February 2026 include new oral treatments for metastatic hormone receptor-positive breast cancer, blood tests for detecting cancer DNA in the bloodstream, and next-generation antibody therapies (businesswire). Additionally, advances focus on early detection, personalized treatment, and innovative therapies such as cancer vaccines and targeted drugs, with promising results from recent clinical trials (aacr.org, dana-farber.org).
Sources
Frequently Asked Questions
What criteria evaluate treatment response in breast cancer solid tumors?
Therasse et al. (2000) in "New Guidelines to Evaluate the Response to Treatment in Solid Tumors" introduced standardized criteria from the International Union Against Cancer and World Health Organization for assessing antitumor activity based on tumor shrinkage from cytotoxic agents. These guidelines measure complete response, partial response, stable disease, and progressive disease. They have been cited 15,648 times and form the basis for clinical trial endpoints.
How do gene expression profiles predict breast cancer outcomes?
Sørlie et al. (2001) in "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications" used cDNA microarrays on 78 cancers to classify tumors into subclasses correlating with clinical outcomes. Van 't Veer et al. (2002) in "Gene expression profiling predicts clinical outcome of breast cancer" and van de Vijver et al. (2002) in "A Gene-Expression Signature as a Predictor of Survival in Breast Cancer" showed gene signatures outperform clinical criteria for prognosis in young patients. These works, cited over 9,000 times each, enable risk stratification.
What factors predict late recurrence in breast cancer?
Nishimura et al. (2013) in "Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer" examined prognostic factors for recurrences beyond 10 years, cited 13,201 times. Histological grade per Elston and Ellis (1991) in "pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up" provides long-term prognostic value. These inform extended monitoring strategies.
What surgical options are supported for invasive breast cancer?
Fisher et al. (2002) in "Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer" found lumpectomy plus irradiation equivalent to mastectomy for survival with clear margins, cited 6,110 times. This supports breast-conserving therapy when cosmetic results are acceptable. The trial provides 20-year data on recurrence and survival.
How does multigene assay predict recurrence in node-negative breast cancer?
Paik et al. (2004) in "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" validated a recurrence score quantifying distant recurrence likelihood in tamoxifen-treated, estrogen-receptor-positive patients, cited 6,234 times. The assay uses 21 genes for risk assessment. It guides decisions on adjuvant chemotherapy.
What is the role of chemotherapy and hormonal therapy in early breast cancer?
The 2005 Lancet overview "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials" analyzed randomized trials showing reduced recurrence and improved 15-year survival. Cited 7,553 times, it quantifies benefits across patient subgroups. These findings shape adjuvant treatment standards.
Open Research Questions
- ? What molecular factors distinguish early from late recurrences beyond 10 years, as hinted in Nishimura et al. (2013)?
- ? How can gene expression signatures from Sørlie et al. (2001) and van 't Veer et al. (2002) be integrated with AJCC staging for precise prognostication?
- ? Which combinations of neoadjuvant therapies optimize outcomes in high-risk HER2-positive cases, per recent DESTINY-Breast11 data?
- ? What limits the generalizability of histological grading reproducibility noted by Elston and Ellis (1991)?
- ? How do long-term effects of adjuvant endocrine plus CDK4/6 inhibitors like palbociclib impact iDFS in HR-positive breast cancer from PALLAS trial follow-up?
Recent Trends
Trastuzumab deruxtecan in DESTINY-Breast04 improved overall and progression-free survival versus chemotherapy in HER2-low metastatic breast cancer.
2025 preprintDESTINY-Breast11 tested neoadjuvant trastuzumab deruxtecan alone or with paclitaxel, trastuzumab, pertuzumab in high-risk HER2-positive early breast cancer, addressing toxicity of standard polychemotherapy.
2025PALLAS trial 5-year analysis confirmed no short-term iDFS benefit from adding palbociclib to endocrine therapy in high-risk HR-positive/HER2-negative early breast cancer.
2025Research Breast Cancer Treatment Studies with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Breast Cancer Treatment Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.